Armata Pharmaceuticals (ARMP) highlighted “positive” results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment ...
Staph infections can affect any part of the body and range from mild to serious. Learn the signs of a staph infection and when to get treatment.
Armata Pharmaceuticals ($ARMP) stock exploded nearly 300% on Wednesday after the biotech firm released encouraging mid-stage ...
A new way to battle bloodborne staph infections could help save lives while combating the rise of antibiotic-resistant bacteria, according to new clinical trial results. Two intravenous doses of the ...
Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial.
As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...
Investing.com -- Armata Pharmaceuticals (NYSE American:ARMP) stock surged 95% following the announcement of positive Phase 2a clinical trial results for its bacteriophage treatment targeting ...
Since the 1940s, antibiotics have been our primary weapon against harmful bacterial infections. But some stubborn pathogens, ...
LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback